DESTINY-CRC01: Maintained efficacy of T-DXd in mCRC

Presented By

Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan

Trial

Phase 2, DESTINY-CRC01

Conference

ASCO GI 2022

21 March, 2022 10:26

Trastuzumab-deruxtecan showed promising activity in patients with HER2-expressing mCRC

Presented By

Dr Takayuki Yoshino, National Cancer Center Hospital East, Japan

Trial

Phase 2, DESTINY-CRC01

Conference

ASCO 2021

12 August, 2021 21:10

Expert

Prof. Salvatore Siena, University of Milan Niguarda Cancer Center, Italy

Trial

Phase 3, DESTINY-CRC01

Conference

ASCO 2020

17 September, 2020 15:00